Frontiers in immunology · 2026
Predicting response to immunochemotherapy in EGFR-mutant lung adenocarcinoma after third-generation TKI resistance using CT radiomics-based habitat imaging.
СтатьяМногоцентровое исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Qie Shuai, Shi Yasong, Li Jingyun, Jia Sicong, Yin Xiaoping
Аннотация
BACKGROUND: Third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) resistance poses a significant therapeutic challenge in advanced lung adenocarcinoma. This study aimed to develop and validate a computed tomography (CT)-based habitat radiomics model for predicting response to immunochemotherapy in EGFR-mutant lung adenocarcinoma patients after TKI resistance.
METHODS: This retrospective multicenter study enrolled 475 patients from two medical centers. Patients were allocated to train (N = 332) and external validation (N = 143) cohorts. Habitat imaging was performed using K-means clustering to partition tumors into three distinct subregions. Radiomic features were extracted from both whole-tumor volumes and habitat subregions. A combined model combining clinical, conventional radiomics, and habitat features was constructed using machine learning algorithms and validated through cross-validation and external testing. The primary endpoint was objective response rate (ORR) based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria, and overall survival (OS) was used as a secondary endpoint.
RESULTS: The combined model demonstrated superior predictive performance with area under the curve (AUC) of 0.904 (95% CI: 0.871-0.937) in the train cohort and 0.890 (95% CI: 0.838-0.942) in the validation cohort, significantly outperforming the clinical model, conventional whole-tumor radiomics model, and habitat model (all P < 0.001). Moreover, Kaplan-Meier analysis based on the risk groups stratified by the combined model revealed significant survival differences, with high-risk groups showing markedly shorter overall survival in both cohorts (training HR = 3.688, validation HR = 2.823, both log-rank P < 0.0001).
CONCLUSION: This study developed and externally validated a CT-based habitat radiomics model for predicting response to immunochemotherapy in EGFR-mutant lung adenocarcinoma after EGFR-TKI resistance. The combined model achieved improved predictive performance compared with single-modality approaches. These findings suggest that incorporating habitat-based features may enhance the characterization of intratumoral heterogeneity and improve treatment response prediction. Notably, the model demonstrated a high negative predictive value, suggesting its potential to reduce unnecessary treatment in predicted non-responders. Further prospective and multi-center validation is warranted.
METHODS: This retrospective multicenter study enrolled 475 patients from two medical centers. Patients were allocated to train (N = 332) and external validation (N = 143) cohorts. Habitat imaging was performed using K-means clustering to partition tumors into three distinct subregions. Radiomic features were extracted from both whole-tumor volumes and habitat subregions. A combined model combining clinical, conventional radiomics, and habitat features was constructed using machine learning algorithms and validated through cross-validation and external testing. The primary endpoint was objective response rate (ORR) based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria, and overall survival (OS) was used as a secondary endpoint.
RESULTS: The combined model demonstrated superior predictive performance with area under the curve (AUC) of 0.904 (95% CI: 0.871-0.937) in the train cohort and 0.890 (95% CI: 0.838-0.942) in the validation cohort, significantly outperforming the clinical model, conventional whole-tumor radiomics model, and habitat model (all P < 0.001). Moreover, Kaplan-Meier analysis based on the risk groups stratified by the combined model revealed significant survival differences, with high-risk groups showing markedly shorter overall survival in both cohorts (training HR = 3.688, validation HR = 2.823, both log-rank P < 0.0001).
CONCLUSION: This study developed and externally validated a CT-based habitat radiomics model for predicting response to immunochemotherapy in EGFR-mutant lung adenocarcinoma after EGFR-TKI resistance. The combined model achieved improved predictive performance compared with single-modality approaches. These findings suggest that incorporating habitat-based features may enhance the characterization of intratumoral heterogeneity and improve treatment response prediction. Notably, the model demonstrated a high negative predictive value, suggesting its potential to reduce unnecessary treatment in predicted non-responders. Further prospective and multi-center validation is warranted.